Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas
Source abstract
Abstract
Activated B-cell-like diffuse large B-cell lymphomas (ABC-DLBCLs) are characterized by constitutive activation of nuclear factor κB driven by the B-cell receptor (BCR) and Toll-like receptor (TLR) pathways. However, BCR-pathway-targeted therapies have limited impact on DLBCLs. Here we used >1,100 DLBCL patient samples to determine immune and extracellular matrix cues in the lymphoid tumour microenvironment (Ly-TME) and built representative synthetic-hydrogel-based B-cell-lymphoma organoids accordingly. We demonstrate that Ly-TME cellular and biophysical factors amplify the BCR-MYD88-TLR9 multiprotein supercomplex and induce cooperative signalling pathways in ABC-DLBCL cells, which reduce the efficacy of compounds targeting the BCR pathway members Bruton tyrosine kinase and mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1). Combinatorial inhibition of multiple aberrant signalling pathways induced higher antitumour efficacy in lymphoid organoids and implanted ABC-DLBCL patient tumours in vivo. Our studies define the complex crosstalk between malignant ABC-DLBCL cells and Ly-TME, and provide rational combinatorial therapies that rescue Ly-TME-mediated attenuation of treatment response to MALT1 inhibitors.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immune Cell Function and Interaction · Lymphoma Diagnosis and Treatment · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Phelan, J. D. et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature 560, 387–391 (2018).10.1038/s41586-018-0290-0 ↗
2. Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679–690 (2018).10.1038/s41591-018-0016-8 ↗
3. Roschewski, M., Staudt, L. M. & Wilson, W. H. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat. Rev. Clin. Oncol. 11, 12–23 (2014).10.1038/nrclinonc.2013.197 ↗
4. Lenz, G. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319, 1676–1679 (2008).10.1126/science.1153629 ↗
5. Fontan, L. et al. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. Blood 137, 788–800 (2021).10.1182/blood.2019004713 ↗
6. Wilson, W. H. et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. Med. 21, 922–926 (2015).10.1038/nm.3884 ↗
7. Young, R. M. & Staudt, L. M. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat. Rev. Drug Disco. 12, 229–243 (2013).10.1038/nrd3937 ↗
8. Young, R. M., Phelan, J. D., Wilson, W. H. & Staudt, L. M. Pathogenic B-cell receptor signaling in lymphoid malignancies: new insights to improve treatment. Immunol. Rev. 291, 190–213 (2019).10.1111/imr.12792 ↗
9. Schmitz, R. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 378, 1396–1407 (2018).10.1056/NEJMoa1801445 ↗
10. Fontan, L. et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer cell 22, 812–824 (2012).10.1016/j.ccr.2012.11.003 ↗
11. Sun, L., Deng, L., Ea, C. K., Xia, Z. P. & Chen, Z. J. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell 14, 289–301 (2004).10.1016/S1097-2765(04)00236-9 ↗
12. Hailfinger, S. et al. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc. Natl Acad. Sci. USA 108, 14596–14601 (2011).10.1073/pnas.1105020108 ↗
13. Fontan, L. et al. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. J. Clin. Invest. 128, 4397–4412 (2018).10.1172/JCI99436 ↗
14. Nagel, D. et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 22, 825–837 (2012).10.1016/j.ccr.2012.11.002 ↗
15. Kotlov, N. et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 11, 1468–1489 (2021).10.1158/2159-8290.CD-20-0839 ↗
16. Wright, G. W. et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37, 551–568 e514 (2020).10.1016/j.ccell.2020.03.015 ↗
17. Scott, D. W. & Gascoyne, R. D. The tumour microenvironment in B cell lymphomas. Nat. Rev. Cancer 14, 517–534 (2014).10.1038/nrc3774 ↗
18. Elgueta, R. et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229, 152–172 (2009).10.1111/j.1600-065X.2009.00782.x ↗
19. Ito, D. et al. CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies. Leuk. Lymphoma 53, 1390–1398 (2012).10.3109/10428194.2011.654337 ↗
20. Nojima, T. et al. In-vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo. Nat. Commun. 2, 465 (2011).10.1038/ncomms1475 ↗
21. Ennishi, D. et al. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 9, 546–563 (2019).10.1158/2159-8290.CD-18-1090 ↗
22. Reddy, A. et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell 171, 481–494.e415 (2017).10.1016/j.cell.2017.09.027 ↗
23. Ni, C. Z. et al. Molecular basis for CD40 signaling mediated by TRAF3. Proc. Natl Acad. Sci. USA 97, 10395–10399 (2000).10.1073/pnas.97.19.10395 ↗
24. Phelps, E. A. et al. Maleimide cross-linked bioactive PEG hydrogel exhibits improved reaction kinetics and cross-linking for cell encapsulation and in situ delivery. Adv. Mater. 24, 64–70 (2012). 62.10.1002/adma.201103574 ↗
25. Graney, P. L. et al. Organoid polymer functionality and mode of Klebsiella pneumoniae membrane antigen presentation regulates ex vivo germinal center epigenetics in young and aged B cells. Adv. Funct. Mater. 30, 2001232 (2020).10.1002/adfm.202001232 ↗
26. Lutolf, M. P. & Hubbell, J. A. Synthesis and physicochemical characterization of end-linked poly(ethylene glycol)-co-peptide hydrogels formed by Michael-type addition. Biomacromolecules 4, 713–722 (2003).10.1021/bm025744e ↗
27. Rodda, L. B. et al. Single-cell RNA sequencing of lymph node stromal cells reveals niche-associated heterogeneity. Immunity 48, 1014–1028 e1016 (2018).10.1016/j.immuni.2018.04.006 ↗
28. Massia, S. P. & Hubbell, J. A. Vascular endothelial cell adhesion and spreading promoted by the peptide REDV of the IIICS region of plasma fibronectin is mediated by integrin α 4 β 1. J. Biol. Chem. 267, 14019–14026 (1992).10.1016/S0021-9258(19)49672-5 ↗
29. Rydholm, A. E., Bowman, C. N. & Anseth, K. S. Degradable thiol-acrylate photopolymers: polymerization and degradation behavior of an in situ forming biomaterial. Biomaterials 26, 4495–4506 (2005).10.1016/j.biomaterials.2004.11.046 ↗
30. Quancard, J. et al. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient. Nat. Chem. Biol. 15, 304–313 (2019).10.1038/s41589-018-0222-1 ↗
31. Richards, K. L. et al. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Res. 73, 5029–5039 (2013).10.1158/0008-5472.CAN-12-3546 ↗
32. Tolar, P., Hanna, J., Krueger, P. D. & Pierce, S. K. The constant region of the membrane immunoglobulin mediates B cell-receptor clustering and signaling in response to membrane antigens. Immunity 30, 44–55 (2009).10.1016/j.immuni.2008.11.007 ↗
33. Clark, A. Y. et al. Integrin-specific hydrogels modulate transplanted human bone marrow-derived mesenchymal stem cell survival, engraftment, and reparative activities. Nat. Commun. 11, 114 (2020).10.1038/s41467-019-14000-9 ↗
34. Arnaout, M. A., Mahalingam, B. & Xiong, J. P. Integrin structure, allostery, and bidirectional signaling. Annu. Rev. Cell Dev. Biol. 21, 381–410 (2005).10.1146/annurev.cellbio.21.090704.151217 ↗
35. Bellis, S. L. Advantages of RGD peptides for directing cell association with biomaterials. Biomaterials 32, 4205–4210 (2011).10.1016/j.biomaterials.2011.02.029 ↗
36. Knight, C. G. et al. Identification in collagen type I of an integrin alpha2 beta1-binding site containing an essential GER sequence. J. Biol. Chem. 273, 33287–33294 (1998).10.1074/jbc.273.50.33287 ↗
37. Zeltz, C. & Gullberg, D. The integrin-collagen connection—a glue for tissue repair? J. Cell Sci. 129, 653–664 (2016).10.1242/jcs.188672 ↗
38. Arana, E., Harwood, N. E. & Batista, F. D. Regulation of integrin activation through the B-cell receptor. J. Cell Sci. 121, 2279–2286 (2008).10.1242/jcs.017905 ↗
39. Carrasco, Y. R. & Batista, F. D. B‐cell activation by membrane‐bound antigens is facilitated by the interaction of VLA‐4 with VCAM‐1. EMBO J. 25, 889–899 (2006).10.1038/sj.emboj.7600944 ↗
40. Weekes, C. D., Kuszynski, C. A. & Sharp, J. G. VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells. Leuk. Lymphoma 40, 631–645 (2001).10.3109/10428190109097661 ↗
41. Headen, D. M. et al. Local immunomodulation Fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance. Nat. Mater. 17, 732–739 (2018).10.1038/s41563-018-0099-0 ↗
42. Landon, A. L. et al. MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL. Nat. Commun. 5, 5413 (2014).10.1038/ncomms6413 ↗
43. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).10.1126/science.1075762 ↗
44. Zheng, M. et al. A mix of S and ΔS variants of STAT3 enable survival of activated B-cell-like diffuse large B-cell lymphoma cells in culture. Oncogenesis 4, e184 (2016).10.1038/oncsis.2015.44 ↗
45. Apoorva, F. N. U. et al. Lymph node stiffness-mimicking hydrogels regulate human B-cell lymphoma growth and cell surface receptor expression in a molecular subtype-specific manner. J. Biomed. Mater. Res. A 105, 1833–1844 (2017).10.1002/jbm.a.36031 ↗
46. Ohto, U. et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature 520, 702–705 (2015).10.1038/nature14138 ↗
47. Scuoppo, C. et al. Repurposing dasatinib for diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA 116, 16981–16986 (2019).10.1073/pnas.1905239116 ↗
48. Battistello, E. et al. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma. Blood 131, 2345–2356 (2018).10.1182/blood-2017-10-809210 ↗
49. Gopal, A. K. et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008–1018 (2014).10.1056/NEJMoa1314583 ↗
50. Kim, S., Shah, S. B., Graney, P. L. & Singh, A. Multiscale engineering of immune cells and lymphoid organs. Nat. Rev. Mater. 4, 355–378 (2019).10.1038/s41578-019-0100-9 ↗
51. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics, 30(7):923–30 (2014).10.1093/bioinformatics/btt656 ↗
52. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 26(1), 139–140 (2010); https://doi.org/10.1093/bioinformatics/btp61610.1093/bioinformatics/btp616 ↗
53. Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W. & Smyth, G. K. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 43(7), e47 (2015); https://doi.org/10.1093/nar/gkv00710.1093/nar/gkv007 ↗
54. Kolde, R. pheatmap: Pretty Heatmaps. R package version 1.0.12 (2019).
55. Shen, Y. et al. Oncogenic role of the SOX9–DHCR24–cholesterol biosynthesis axis in IGH-BCL2+ diffuse large B-cell lymphomas. Blood 139, 73–86 (2022).10.1182/blood.2021012327 ↗
56. Stringer, C., Wang, T., Michaelos, M. & Pachitariu, M. Cellpose: a generalist algorithm for cellular segmentation. Nat Methods 18, 100–106 (2021).10.1038/s41592-020-01018-x ↗
57. Apoorva, F. et al. How biophysical forces regulate human B cell lymphomas. Cell Rep. 23, 499–511 (2018).10.1016/j.celrep.2018.03.069 ↗
58. Purwada, A. et al. Ex vivo engineered immune organoids for controlled germinal center reactions. Biomaterials 63, 24–34 (2015).10.1016/j.biomaterials.2015.06.002 ↗
59. Purwada, A. et al. Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells. Biomaterials 198, 27–36 (2019).10.1016/j.biomaterials.2018.06.034 ↗
60. Purwada, A., Shah, S. B., Beguelin, W., Melnick, A. M. & Singh, A. Modular immune organoids with integrin ligand specificity differentially regulate ex vivo B cell activation. ACS Biomater. Sci. Eng. 3, 214–225 (2017).10.1021/acsbiomaterials.6b00474 ↗